Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Celgene Partner on Targeted Protein Degradation for Drug Discovery

NEW YORK (GenomeWeb) — Evotec said today that it has entered into a drug-discovery alliance with biotech firm Celgene that will focus on targeted protein degradation.

Under the terms of the deal, the partners will use Evotec's Panomics platform — which integrates genomic, transcriptomic, and proteomic data for analysis with the company's PanHunter bioinformatic technology — to identify difficult-to-track drug targets.

Celgene will hold the exclusive rights to all drug candidates arising from the alliance. Evotec will receive an undisclosed upfront payment from Celgene, and stands to receive milestones and tiered, potentially double-digit royalty payments on each licensed program.

Additional terms were not disclosed.

"Addressing traditionally undruggable targets via targeted protein degradation is a highly attractive and promising approach which has not been explored systematically," Evotec CSO Cord Dohrmann said in a statement.

The deal marks the third strategic drug-discovery partnership between Evotec and Celgene, which previously forged alliances in oncology and neurodegenerative disease.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.